On July 7, Hyperliquid Strategies fell 8.11% in regular trading, trading at $8.365/share, with turnover of $52.40 million.

Within the Biotechnology sector where Hyperliquid Strategies belongs, among individual stocks, Vertex Pharmaceuticals down 1.77%, AbbVie up 1.13%, Gilead Sciences up 4.44%, Moderna down 2.80%, Natera down 0.59%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)